Irinotecan Hikma

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Hikma, is a topoisomerase I inhibitor presented as a sterile powder for intravenous infusion. It is used to treat metastatic colorectal cancer and as adjuvant therapy for colorectal cancer in adult patients.

GNH USA supplies Irinotecan Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution. Clients benefit from reliable logistics, temperature‑controlled shipping where required, and dedicated technical support throughout the supply chain.

Irinotecan Hikma is employed in oncology regimens targeting colorectal malignancies.

- Metastatic colorectal cancer: improves overall survival and disease control. - Adjuvant colorectal cancer: reduces risk of recurrence after surgical resection. - Palliative colorectal cancer: alleviates tumor burden and associated symptoms.

Irinotecan may cause a range of adverse reactions.

Common Side Effects: - Diarrhea: often severe and may require antidiarrheal therapy. - Nausea and vomiting: managed with standard antiemetics. - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: generalized tiredness during treatment.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils, a medical emergency. - Severe colitis or intestinal perforation: life‑threatening gastrointestinal complications. - Hepatotoxicity: marked elevation of liver enzymes. - Hypersensitivity reactions: including rash, bronchospasm, or anaphylaxis.

Before initiating Irinotecan Hikma, consider the following safety measures.

- Pregnancy: category D – avoid use unless potential benefits justify the risk. - Breastfeeding: not recommended as drug may be excreted in milk. - Renal impairment: assess renal function and adjust dosing if necessary. - Hepatic impairment: use with caution; monitor liver enzymes closely. - Concomitant myelosuppressive agents: increased risk of bone‑marrow suppression. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce irinotecan exposure. - UGT1A1 inhibitors (e.g., atazanavir): can increase SN‑38 levels and toxicity. - Concurrent myelosuppressive chemotherapy: heightened bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Antiemetics such as ondansetron: may affect drug metabolism. - Fluoroquinolone antibiotics: potential additive neutropenia. - Warfarin: monitor INR as irinotecan may influence anticoagulation.